Skin News and Research

RSS

DoD awards Regenicin and Lonza $18 million to develop PermaDerm for severe burns

The U.S. Department of Defense recently awarded more than $18 million in funding to a unit of Lonza Group, Ltd. for the development and commercialization of the therapeutic candidate, PermaDerm™ for the treatment of severe burns among U.S. troops and civilians. The funding was announced at a conference celebrating advancements in regenerative medicine on November 9th in Walkersville, MD.

23 Nov 2010

Confidisc introduces new anti-illegal drug syringe

ConfiDisc's anti-illegal drug syringe is an integral part of its syringe injection system. The disc, which is attached to the hub of a syringe device, acts as a physical barrier.

22 Nov 2010

Researchers develop three-dimensional cancer cell from normal human tissue in culture dish

Researchers at the Stanford University School of Medicine have successfully transformed normal human tissue into three-dimensional cancers in a tissue culture dish for the first time. Watching how the cells behave as they divide and invade surrounding tissue will help physicians better understand how human cancers act in the body. The new technique also provides a way to quickly and cheaply test anti-cancer drugs without requiring laboratory animals.

22 Nov 2010

CSU invents artificial body parts that look, feel, behave, and bleed like real skin, muscles and vessels

In the last 50 years, modern medicine has made astounding advances in surgery, yet many of today's veterinary and human medicine students still hone basic surgical and suturing skills on carpet pads and pig's feet before transitioning to a live patient. An invention by Colorado State University veterinarians provides students with artificial body parts that look, feel, behave, and even bleed just like real skin, muscles and vessels.

20 Nov 2010

Tips to maintain an upperhand on bedbugs

Think twice before combing the alleyways and resale stores for a bargain - one man's trash may be more than a treasure, as several Chicagoans recently discovered.

20 Nov 2010

Genetic differences impact winter vitamin D status

Vitamin D is somewhat of an unusual "vitamin," because it can be made in the body from sunlight and most foods do not contain vitamin D unless added by fortification. Synthesis of vitamin D in the body requires exposure to ultraviolet light and can be influenced by genetics, skin color, and sun exposure.

20 Nov 2010

Cascade reaffirms position on non-invasive detection of melanoma by SkinSpect device

Cascade Technologies, Corp. announced today that, in response to significant recent attention to the Food and Drug Administration (FDA) panel evaluation of Mela Sciences' MelaFind device, the company has received a number of inquiries about its similar instrument.

20 Nov 2010

Obagi Medical Products prices secondary offering

Obagi Medical Products, Inc., a leader in topical aesthetic and therapeutic skin health systems, today announced the pricing of the secondary public offering of 2,690,244 shares of its common stock by the Stonington Capital Appreciation 1994 Fund, L.P. and the Zein and Samar Obagi Family Trust, at a public offering price of $10.25 per share.

20 Nov 2010

Vascular Disease Foundation urges diabetic patients to be alert about P.A.D. signs

P.A.D. occurs when arteries in the legs become narrowed or clogged with fatty deposits, reducing blood flow to the legs. This can result in leg muscle pain when walking, disability, amputation, and poor quality of life. Blocked arteries found in people with P.A.D. can be a red flag that other arteries, including those in the heart and brain, may also be blocked - increasing the risk of a heart attack or stroke.

20 Nov 2010

Reprogrammed amniotic fluid cells can generate iPS cells

Reprogrammed amniotic fluid cells can generate all types of body cells. High hopes rest on stem cells: one day, they may be used to treat many diseases. To date, embryos are the main source of these cells, but this raises ethical problems. Scientists at the Max Planck Institute for Molecular Genetics in Berlin have now managed to convert amniotic fluid cells into pluripotent stem cells.

20 Nov 2010

Threshold Pharmaceuticals announces results on TH-302 prodrug for cancers at EORTC-NCI-AACR Symposium

Threshold Pharmaceuticals, Inc. today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place in Berlin, Germany from November 16 to19, 2010.

19 Nov 2010

ACE-041 drug may provide new option to treat cancer

Researchers have found that a newly developed drug, which is aimed at a particular receptor involved in the development of blood vessels that sustain tumour growth, is active in patients with advanced cancers and, in some cases, has halted the progress of the disease. The drug, ACE-041, targets a different molecular pathway to other anti-angiogenesis drugs and may provide a new option to treat cancer.

19 Nov 2010

FDA clears Multi-Lead Trialing Cable for SCS therapy

Medtronic Inc., the leader in spinal cord stimulation for more than 25 years, today announced U.S. Food and Drug Administration (FDA) clearance and the global launch of the Multi-Lead Trialing Cable for use in the patient screening test for Medtronic spinal cord stimulation (SCS) therapy.

19 Nov 2010

Scientists discover bone matrix plays a vital role in tissue hardening

Scientists are reporting the first direct evidence that a subtle change in the physical properties of a tissue can affect its function. The finding has immediate implications for understanding several rare hearing disorders, they said, and ultimately could offer insight into such conditions as osteoporosis, arthritis, cardiovascular disease and cancer.

19 Nov 2010

Elorac announces results of Phase III CPO solution studies for acne at Healthcare Conference in New York

Elorac, Inc., a rapidly growing specialty pharmaceutical company focused on the treatment of dermatological disorders, announced results of two Phase III studies of its patented Carbamide Peroxide (CPO) solution for the treatment of inflammatory acne vulgaris and rosacea at the Lazard Capital Markets 7th Annual Healthcare Conference in New York.

19 Nov 2010

Technogym launches first U.S. wellness center

Technogym, a world leader in fitness and wellness, launches their first U.S. wellness center in the U.S. in Soho, New York, which will be a one-stop education center, retail location and showroom.

18 Nov 2010

Circassia announces positive result from phase II T-cell vaccine study for house dust mite allergy

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced successful clinical results from a phase II study of its T-cell vaccine targeting house dust mite allergy.

18 Nov 2010

Spleen cells may do more harm than good at site of spinal cord injury

The spleen, an organ that helps the body fight infections, might also be a source of the cells that end up doing more harm than good at the site of a spinal cord injury, new research suggests.

18 Nov 2010

Low allergenic wines with less potential to trigger allergy symptoms

Scientists have identified a mysterious culprit that threatens headaches, stuffy noses, skin rash and other allergy symptoms when more than 500 million people worldwide drink wine. The discovery could help winemakers in developing the first low allergenic vintages - reds and whites with less potential to trigger allergy symptoms, they say. The new study appears in ACS' monthly Journal of Proteome Research.

18 Nov 2010

Multidisciplinary clinic approach can improve survival in patients with aggressive prostate cancer

A research team from the National Cancer Institute (NCI) designated Kimmel Cancer Center (KCC) at Jefferson has concluded for the first time that a multidisciplinary clinic approach to aggressive prostate cancer can improve survival in patients. The results from the 15-year study of the multidisciplinary clinic can be found in the November issue of Journal of Oncology Practice.

18 Nov 2010

Skin News and Research

DoD awards Regenicin and Lonza $18 million to develop PermaDerm for severe burns

Confidisc introduces new anti-illegal drug syringe

Researchers develop three-dimensional cancer cell from normal human tissue in culture dish

CSU invents artificial body parts that look, feel, behave, and bleed like real skin, muscles and vessels

Tips to maintain an upperhand on bedbugs

Genetic differences impact winter vitamin D status

Cascade reaffirms position on non-invasive detection of melanoma by SkinSpect device

Obagi Medical Products prices secondary offering

Vascular Disease Foundation urges diabetic patients to be alert about P.A.D. signs

Reprogrammed amniotic fluid cells can generate iPS cells

Threshold Pharmaceuticals announces results on TH-302 prodrug for cancers at EORTC-NCI-AACR Symposium

ACE-041 drug may provide new option to treat cancer

FDA clears Multi-Lead Trialing Cable for SCS therapy

Scientists discover bone matrix plays a vital role in tissue hardening

Elorac announces results of Phase III CPO solution studies for acne at Healthcare Conference in New York

Technogym launches first U.S. wellness center

Circassia announces positive result from phase II T-cell vaccine study for house dust mite allergy

Spleen cells may do more harm than good at site of spinal cord injury

Low allergenic wines with less potential to trigger allergy symptoms

Multidisciplinary clinic approach can improve survival in patients with aggressive prostate cancer

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News